Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2 Study to Evaluate the Safety and Efficacy of MK-1045 Monotherapy or in Combination With Other Anticancer Agents in Participants With Non-Hodgkin Lymphoma

NCT07519772 is registered in ClinicalTrials.gov with Merck Sharp & Dohme LLC as lead sponsor.

NCT NCT07519772
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07519772 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2 Study to Evaluate the Safety and Efficacy of MK-1045 Monotherapy or in Combination With Other Anticancer Agents in Participants With Non-Hodgkin Lymphoma
Lead sponsor
Merck Sharp & Dohme LLC
Phase
Phase 1/2
Overall status
Recruiting
Start date
May 3, 2026
Completion date
April 1, 2031
Enrollment
280 (estimated)
Sites
46

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma, follicular, lymphoma, large b-cell, diffuse, lymphoma, non-hodgkin